Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Dollar index climbs to 103.50 as Fed hike bets lift US currency

    November 17, 2026

    Mpox cases top 1,000 in Brazil as first 2026 death confirmed

    November 16, 2026

    Diesel slips to $5.998 a gallon as crude drops and demand eases

    November 16, 2026
    Philadelphia StarPhiladelphia Star
    • Home
    • Contact Us
    • Disclaimer
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Audi launches Q9 and high performance SQ9 V8 SUV variants

      July 31, 2026

      Ford recalls nearly 420,000 SUVs over seat belt issue

      June 4, 2026

      Mercedes-Benz USA unveils 2027 S-Class with MB.OS tech

      January 30, 2026

      Ford issues US recall for Escape Focus Explorer and Lincoln MKC

      January 22, 2026
    • Business

      Dollar index climbs to 103.50 as Fed hike bets lift US currency

      November 17, 2026

      Diesel slips to $5.998 a gallon as crude drops and demand eases

      November 16, 2026

      Oil market to return to surplus as Gulf exports recover: IEA

      November 14, 2026

      Spot gold drops 2.9% to $3,871 on Fed hike bets, firm dollar

      November 13, 2026

      Bitcoin rally drives Trump Media to $409.7 million Q3 profit

      November 11, 2026
    • Entertainment

      Sony confirms God of War trilogy remake and PS5 prequel

      February 13, 2026

      Disney’s Fantastic Four beats Superman in box office debut

      July 27, 2025

      Disney and Marvel’s R-rated film hits billion-dollar milestone

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024

      USHER’s pre-Super Bowl experience on Apple Music

      February 7, 2024
    • Health

      Mpox cases top 1,000 in Brazil as first 2026 death confirmed

      November 16, 2026

      Together for Science and Health unites 240 groups behind WHO

      November 11, 2026

      Measles surge in US tops 4,580 as Pennsylvania outbreak grows

      October 26, 2026

      Microsoft AI doubles physician accuracy on complex cases

      October 24, 2026

      Walgreens eye drops included in nationwide sterility recall

      October 5, 2026
    • Lifestyle

      Apple and ISSEY MIYAKE unveil new 3D-knit iPhone Pocket

      November 13, 2025

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023

      How Nike’s Kobe 8 Protro Halo Marks an Emotional Milestone

      August 29, 2023
    • Luxury

      Price hikes and lack of innovation erode luxury market confidence

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      Thousands of US flights disrupted by FAA ground stop

      November 14, 2026

      Latvia puts AI and drones on UN Security Council agenda

      November 12, 2026

      Guterres calls Ibero-America a cultural superpower in Madrid

      November 6, 2026

      Democrats flip more than two dozen GOP House seats

      November 5, 2026

      Democrats flip Texas, Kansas Senate seats to take Congress

      November 4, 2026
    • Sports

      Spain beat Portugal to reach World Cup quarter-finals

      July 7, 2026

      Norway beats Brazil to reach World Cup last eight

      July 6, 2026

      Egypt oust Australia on penalties to reach World Cup last 16

      July 4, 2026

      Spain defeats Austria 3-0 to enter World Cup last 16

      July 3, 2026

      Mexico reaches World Cup last 16 with Ecuador win

      July 2, 2026
    • Technology

      Apple iPhone Duo delivers the most cohesive foldable yet

      November 2, 2026

      MacBook Pro gets PROLED XDR screen and Touch on Mac

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026

      Meta halts Muse chat links after 6,800 found in DNS records

      October 23, 2026

      NASA rover plans set stage for permanent Moon base

      October 23, 2026
    • Travel

      Holiday travel airfare deals enter peak booking season

      October 3, 2026

      US keeps Belgium at Level 2 in updated travel advisory

      August 6, 2026

      Maine tourism feels strain as Canadian travel drops

      March 30, 2026

      Houston Bush airport warns of four-hour TSA lines

      March 26, 2026

      U.S. inbound travel declined in 2025 even as global tourism rose

      January 28, 2026
    Philadelphia StarPhiladelphia Star
    Home » InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Phase 2 Trial Progress for NV-387 in Ebola and Mpox Treatments
    IBN

    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Phase 2 Trial Progress for NV-387 in Ebola and Mpox Treatments

    November 17, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report on Form 10-Q for the fiscal quarter ended Sept. 30, 2026, highlighting the advancement of its broad-spectrum antiviral candidate NV-387 Oral Gummies into two Phase 2 clinical trials. Enrollment began Sept. 23 for a trial evaluating NV-387 against Ebola Bundibugyo virus disease in the Democratic Republic of the Congo, while a separate Phase 2 trial site opened the same day to evaluate the treatment for mpox. The company said it has funded the Ebola trial independently and established clinical testing infrastructure, including on-site molecular diagnostic capabilities, to support its research.

    NanoViricides also highlighted U.S. Food and Drug Administration (“FDA”) Orphan Drug and Rare Pediatric Disease designations granted to NV-387 for measles treatment in April and May 2026, respectively. The company plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to advance development. NV-387 remains investigational, with its effectiveness for these indications under clinical evaluation.

    To view the full press release, visit https://ibn.fm/HChFn

    About NanoViricides

    NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

    The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

    NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

    The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

    NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

    About InvestorWire

    InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

    For more information, please visit https://www.InvestorWire.com

    Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

    InvestorWire
    Austin, Texas
    www.InvestorWire.com
    512.354.7000 Office
    Editor@InvestorWire.com

    InvestorWire is powered by IBN

    Related Posts

    AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTFD) Featured in AINewsWire Editorial on AI Infrastructure and Semiconductor Equipment Growth

    November 17, 2026

    InvestorNewsBreaks – Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) Featured in MiningNewsWire Editorial on Gold, Silver and Critical Minerals Investment Opportunities

    November 17, 2026

    InvestorNewsBreaks – Mobilicom Limited (NASDAQ: MOB) Secures $863,000 Follow-On Defense Order, Bringing Program Total to $4.7 Million

    November 17, 2026

    TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Secures Energy Sector Survey Contracts With Potential Follow-On Work Totaling Nearly C$1 Million

    November 17, 2026

    TechMediaBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Highlights Upcoming GT Scout Launch and Record Q3 Results in Shareholder Letter

    November 17, 2026

    BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

    November 17, 2026
    Latest News

    Dollar index climbs to 103.50 as Fed hike bets lift US currency

    November 17, 2026

    Mpox cases top 1,000 in Brazil as first 2026 death confirmed

    November 16, 2026

    Diesel slips to $5.998 a gallon as crude drops and demand eases

    November 16, 2026

    Oil market to return to surplus as Gulf exports recover: IEA

    November 14, 2026

    Thousands of US flights disrupted by FAA ground stop

    November 14, 2026

    Spot gold drops 2.9% to $3,871 on Fed hike bets, firm dollar

    November 13, 2026

    Latvia puts AI and drones on UN Security Council agenda

    November 12, 2026

    Bitcoin rally drives Trump Media to $409.7 million Q3 profit

    November 11, 2026
    © 2026 Philadelphia Star | All Rights Reserved
    • Home
    • Contact Us
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.